All In Biotech

Free tool

FAERS Monitor: Thalitone

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 019574 or its brand name (Thalitone, Chlorthalidone). Reports on generic versions are filed under their own applications.

Reports

11,770

Serious

7,408

63% of reports

Hospitalization

3,768

Death reported

704

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue919
  • nausea758
  • drug ineffective756
  • diarrhoea700
  • dizziness598
  • pain569
  • off label use564
  • headache557
  • dyspnoea536
  • acute kidney injury476
  • chronic kidney disease461
  • arthralgia457
  • asthenia447
  • hypertension410
  • blood pressure increased399

Reports by year received

View as table
YearReports
200432
200540
200661
200744
200868
200988
2010128
2011171
2012215
2013224
2014344
2015535
2016671
2017615
2018785
2019953
2020887
2021954
20221,064
20231,009
20241,056
20251,135
2026691

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,042,389 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
chronic kidney diseaseSignal46110.910.04,126
acute kidney injurySignal4765.65.11,789
blood pressure increasedSignal3994.74.21,154
hypertensionSignal4103.53.1722
dizzinessSignal5982.12.0372
astheniaSignal4472.11.9270
fatigueSignal9192.12.0556
arthralgia4572.01.8220
diarrhoea7001.91.8327
nausea7581.71.6232
dyspnoea5361.71.6155
pain5691.71.5151
headache5571.61.5124
off label use5641.21.112
drug ineffective7561.01.00

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.